Endogenous Cushing Syndrome
Endocrinology
1
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
RecordatiFrance - Saint-Victor
2 programs1
Intervention/TreatmentPhase 41 trial
OsilodrostatN/ASmall Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
RecordatiIntervention/Treatment
RecordatiOsilodrostat
Clinical Trials (2)
Total enrollment: 19 patients across 2 trials
Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome
Start: Oct 2023Est. completion: Nov 20257 patients
Phase 4Unknown
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
Start: Jul 2024Est. completion: Aug 202712 patients
N/ARecruiting
Related Jobs in Endocrinology
Research Associate I/II - Biology
Marea Therapeutics
South San Francisco
1w ago
$90K - $120K/yr
Associate Director, Clinical Operations
Marea Therapeutics
South San Francisco
3w ago
$190K - $210K/yr
Associate Director/Director, Regulatory Affairs
Marea Therapeutics
South San Francisco
1mo ago
$185K - $240K/yr
Medical Science Liaison (rare diseases)
Amgen
Poland - Lódz
1mo ago
Senior/Executive Director, Analytical Development
Marea Therapeutics
South San Francisco
1mo ago
$250K - $295K/yr
Senior Clinical Scientist - Job ID: 1845
Ascendis Pharma
Palo Alto, California (Hybrid)
2mo ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 19 patients
Small Molecule is the dominant modality (100% of programs)
1 companies competing in this space